[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20021400D0 - Terapeutiske konazolinderivater - Google Patents

Terapeutiske konazolinderivater

Info

Publication number
NO20021400D0
NO20021400D0 NO20021400A NO20021400A NO20021400D0 NO 20021400 D0 NO20021400 D0 NO 20021400D0 NO 20021400 A NO20021400 A NO 20021400A NO 20021400 A NO20021400 A NO 20021400A NO 20021400 D0 NO20021400 D0 NO 20021400D0
Authority
NO
Norway
Prior art keywords
conazoline
therapeutic
derivatives
therapeutic conazoline
conazoline derivatives
Prior art date
Application number
NO20021400A
Other languages
English (en)
Other versions
NO20021400L (no
Inventor
Andrew Austen Mortlock
Nicholas John Keen
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20021400D0 publication Critical patent/NO20021400D0/no
Publication of NO20021400L publication Critical patent/NO20021400L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20021400A 1999-09-21 2002-03-20 Terapeutiske kinazolinderivater NO20021400L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9922171.5A GB9922171D0 (en) 1999-09-21 1999-09-21 Chemical compounds
PCT/GB2000/003593 WO2001021597A1 (en) 1999-09-21 2000-09-19 Therapeutic quinazoline derivatives

Publications (2)

Publication Number Publication Date
NO20021400D0 true NO20021400D0 (no) 2002-03-20
NO20021400L NO20021400L (no) 2002-05-06

Family

ID=10861217

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021400A NO20021400L (no) 1999-09-21 2002-03-20 Terapeutiske kinazolinderivater

Country Status (24)

Country Link
US (1) US7235559B1 (no)
EP (1) EP1218355A1 (no)
JP (1) JP2003509500A (no)
KR (1) KR20020030123A (no)
CN (1) CN1391563A (no)
AR (1) AR025735A1 (no)
AU (1) AU762697B2 (no)
BG (1) BG106526A (no)
BR (1) BR0014137A (no)
CA (1) CA2384296A1 (no)
CO (1) CO5200783A1 (no)
CZ (1) CZ20021008A3 (no)
EE (1) EE200200118A (no)
GB (1) GB9922171D0 (no)
HK (1) HK1046685A1 (no)
HU (1) HUP0300205A3 (no)
IL (1) IL148496A0 (no)
IS (1) IS6310A (no)
NO (1) NO20021400L (no)
PL (1) PL354870A1 (no)
SK (1) SK3872002A3 (no)
TR (1) TR200200717T2 (no)
WO (1) WO2001021597A1 (no)
ZA (1) ZA200202232B (no)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2305081T3 (es) 2000-06-28 2008-11-01 Astrazeneca Ab Derivados de quinozolina sustituidos y su uso como inhibidores.
AU2002217999A1 (en) 2000-11-01 2002-05-15 Cor Therapeutics, Inc. Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides
JP2002293773A (ja) * 2001-03-30 2002-10-09 Sumika Fine Chemicals Co Ltd キナゾリン誘導体の製造方法
WO2003000188A2 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
WO2003035602A1 (fr) * 2001-10-25 2003-05-01 Sankyo Company, Limited Modulateurs lipidiques
PL211694B1 (pl) * 2001-12-24 2012-06-29 Astrazeneca Ab Podstawiona pochodna chinazoliny, jej zastosowania oraz jej kompozycja farmaceutyczna
BR0306982A (pt) 2002-01-17 2004-10-26 Neurogen Corp Composto ou um sal deste farmaceuticamente aceitável, composição farmacêutica, métodos para reduzir a condutância de cálcio de um receptor da capsaicina celular, para inibir a ligação de ligando vanilóide a um receptor da capsaicina in vitro e em um paciente, para tratar uma condição responsiva à modulação do receptor da capsaicina em um paciente, para tratar a dor em um paciente, para tratar coceira em um paciente, para tratar tosse ou soluço em um paciente, promover a perda de peso em um paciente obeso, e para determinar a presença ou ausência de receptor da capsaicina em uma amostra, preparação farmacêutica embalada, e, uso de um composto
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US7176310B1 (en) 2002-04-09 2007-02-13 Ucb Sa Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents
EP1548008A4 (en) * 2002-08-23 2008-08-06 Kirin Pharma Kk COMPOUND HAVING BETA-TRANSFORMING GROWTH FACTOR INHIBITORY ACTIVITY AND DRUG CONTAINING COMPOSITION
CA2503371C (en) 2002-11-04 2011-01-11 Astrazeneca Ab Quinazoline derivatives as src tyrosine kinase inhibitors
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
RS20060097A (en) 2002-12-20 2008-11-28 Pfizer Products Inc., Pyrimidine derivatives for the treatment of abnormal cell growth
WO2004056812A1 (en) * 2002-12-23 2004-07-08 Astrazeneca Ab 4- (pyridin-4-ylamino) -quinazoline derivatives as anti-tumor agents
AU2003299943A1 (en) * 2002-12-23 2004-07-22 Ariad Pharmaceuticals, Inc. Heterocycles and uses thereof
WO2004056801A1 (en) * 2002-12-23 2004-07-08 Astrazeneca Ab Quinazoline derivatives
BRPI0317717B8 (pt) 2002-12-24 2021-05-25 Astrazeneca Ab composto, composição farmacêutica, e uso de um composto
CA2508921A1 (en) 2002-12-24 2004-07-15 Astrazeneca Ab Quinazoline compounds
AU2003294142A1 (en) * 2002-12-24 2004-07-22 Astrazeneca Ab Therapeutic quinazoline derivatives
JP4709139B2 (ja) * 2003-04-16 2011-06-22 アストラゼネカ アクチボラグ 癌の治療のためのキナゾリン誘導体
ES2308182T3 (es) * 2003-06-02 2008-12-01 Astrazeneca Ab Derivadosde (3-((quinazolin-4-il)amino)-1h-pirazol-1-il)acetamida y compuestos relacionados como inhibidores de quinasas aurora para el tratamiento de enfermedades proliferativas tales como el cancer.
WO2004108707A1 (en) * 2003-06-05 2004-12-16 Astrazeneca Ab Pyridazinil quinazoline derivatives for use in the treatment of tumours
WO2004108711A1 (en) * 2003-06-05 2004-12-16 Astrazeneca Ab Pyrazinil quinazoline derivatives for use in the treatment of tumours
WO2004108710A1 (en) * 2003-06-05 2004-12-16 Astrazeneca Ab 4-pyrimidinyl quinazoline derivatives for use in the treatment of tumours
TW200505452A (en) * 2003-06-17 2005-02-16 Astrazeneca Ab Chemical compounds
US7329664B2 (en) 2003-07-16 2008-02-12 Neurogen Corporation Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
EP1660090B1 (en) * 2003-08-14 2012-11-21 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
WO2005030140A2 (en) 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and methods of use
DE602004022318D1 (de) * 2003-10-14 2009-09-10 Supergen Inc Proteinkinaseinhibitoren
US20090099165A1 (en) 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
CA2540342A1 (en) * 2003-10-31 2005-05-12 Neurogen Corporation 4-amino (aza) quinoline derivatives as capsaicin receptor agonists
ES2315834T3 (es) 2004-02-03 2009-04-01 Astrazeneca Ab Derivados de quinazolina.
WO2005111016A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
WO2005111022A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidines derivatives for the treatment of abnormal cell growth
WO2005111024A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
TW200624431A (en) 2004-09-24 2006-07-16 Hoffmann La Roche Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
US7285569B2 (en) 2004-09-24 2007-10-23 Hoff Hoffmann-La Roche Inc. Tricycles, their manufacture and use as pharmaceutical agents
BRPI0516093A (pt) 2004-10-12 2008-08-19 Astrazeneca Ab derivado de quinazolina, processo para a preparação do mesmo, composição farmacêutica, uso de um derivado de quinazolina, e, método para tratamento de distúrbios proliferativos celulares em um animal de sanque quente
WO2006044687A2 (en) 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
EP1863792B1 (en) * 2005-03-28 2009-01-21 Brystol-Myers Squibb Company Atp competitive kinase inhibitors
JP2008535876A (ja) 2005-04-14 2008-09-04 エフ.ホフマン−ラ ロシュ アーゲー アミノピラゾール誘導体、これらの製造、及び医薬製剤としての使用。
GB0509227D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
WO2007099323A2 (en) * 2006-03-02 2007-09-07 Astrazeneca Ab Quinoline derivatives
GEP20135728B (en) 2006-10-09 2013-01-25 Takeda Pharmaceuticals Co Kinase inhibitors
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
MX2009007610A (es) 2007-02-06 2009-07-24 Boehringer Ingelheim Int Heterociclicos biciclicos, medicamentos que contienen estos compuestos, su utilizacion y procedimientos para su preparacion.
ES2470341T3 (es) 2007-04-05 2014-06-23 Amgen, Inc Moduladores de la aurora cinasa y método de uso
CN101215274B (zh) * 2007-12-27 2011-05-04 上海北卡医药技术有限公司 N取代吗啉类有机化合物的制备工艺
BRPI0907916A2 (pt) 2008-02-07 2015-07-28 Boehringer Ingelheim Int Heterociclos espirociclos, medicamentos contendo esses compostos, e processos para preparar os mesmos
ES2413806T3 (es) 2008-03-20 2013-07-17 Amgen Inc. Moduladores de la aurora cinasa y método de uso
BRPI0912170A2 (pt) 2008-05-13 2015-10-13 Astrazeneca Ab composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente
CA2733153C (en) 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
WO2010019473A1 (en) 2008-08-14 2010-02-18 Amgen Inc. Aurora kinase modulators and methods of use
EP2340244A4 (en) * 2008-10-14 2012-07-25 Ning Xi COMPOUNDS AND APPLICATION PROCEDURES
EP2241565A1 (en) 2009-01-15 2010-10-20 Universität Leipzig Aurora kinase inhibitors compounds
NZ618004A (en) 2009-01-16 2015-06-26 Exelixis Inc Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl]oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
JP5583751B2 (ja) * 2009-03-21 2014-09-03 クイ ニング アミノエステル誘導体、その塩、及び使用方法
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
CA2816957A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
GB201021103D0 (en) * 2010-12-13 2011-01-26 Univ Leuven Kath New compounds for the treatment of neurodegenerative diseases
CN103304489B (zh) * 2012-03-16 2015-03-11 中国农业科学院兰州畜牧与兽药研究所 嘧啶苯甲酰胺类化合物及其制备和应用
MY191804A (en) 2013-09-16 2022-07-15 Astrazeneca Ab Therapeutic polymeric nanoparticles and methods of making and using same
AU2014373773C1 (en) 2014-01-01 2019-06-27 Medivation Technologies Llc Compounds and methods of use
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
EP3939973A1 (en) 2015-07-06 2022-01-19 Alkermes, Inc. Hetero-halo inhibitors of histone deacetylase
EP3184507A1 (en) * 2015-12-22 2017-06-28 Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO Preparation of phenyl compounds
AU2018207402B2 (en) 2017-01-11 2023-09-28 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
WO2019032528A1 (en) 2017-08-07 2019-02-14 Rodin Therapeutics, Inc BICYCLIC HISTONE DEACETYLASE INHIBITORS
CN110746398A (zh) * 2019-10-18 2020-02-04 刘沛友 4-杂环取代喹唑啉类衍生物及其制备方法和用途
CN114436975B (zh) * 2022-01-26 2023-10-31 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 2-三氟甲基-4-氨基喹唑啉类化合物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
US6258820B1 (en) * 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
JP2002539262A (ja) * 1999-03-19 2002-11-19 パーカー ヒューズ インスティテュート キナゾリン化合物製剤および治療におけるその使用

Also Published As

Publication number Publication date
CO5200783A1 (es) 2002-09-27
EP1218355A1 (en) 2002-07-03
IS6310A (is) 2002-03-19
BG106526A (en) 2002-10-31
CZ20021008A3 (cs) 2002-06-12
TR200200717T2 (tr) 2002-06-21
SK3872002A3 (en) 2002-12-03
KR20020030123A (ko) 2002-04-22
HUP0300205A2 (en) 2003-05-28
US7235559B1 (en) 2007-06-26
PL354870A1 (en) 2004-03-08
JP2003509500A (ja) 2003-03-11
HUP0300205A3 (en) 2003-08-28
WO2001021597A1 (en) 2001-03-29
CA2384296A1 (en) 2001-03-29
ZA200202232B (en) 2003-08-27
IL148496A0 (en) 2002-09-12
NO20021400L (no) 2002-05-06
AR025735A1 (es) 2002-12-11
GB9922171D0 (en) 1999-11-17
CN1391563A (zh) 2003-01-15
BR0014137A (pt) 2002-05-21
EE200200118A (et) 2003-04-15
HK1046685A1 (zh) 2003-01-24
AU7301900A (en) 2001-04-24
AU762697B2 (en) 2003-07-03

Similar Documents

Publication Publication Date Title
NO20021400D0 (no) Terapeutiske konazolinderivater
DK1637127T3 (da) Terapeutisk mikroskum
IS2277B (is) Meðferðarlegar bíarýl afleiður
IS2116B (is) 4-fenyl-pyridin afleiður
NO20021077L (no) Amino-triazolopyridin-derivater
DE60009747D1 (de) Admantan-derivate
ATE293104T1 (de) Thiazolylamid-derivate
PT1235558E (pt) Agentes terapeuticos
IS6128A (is) 13-Metýl-erýþrómýsín afleiður
DK1187814T3 (da) 5-phenyl-pyrimidinderivater
ATE338021T1 (de) Substituierte 2-dialkylaminoalkylbiphenyl- derivate
NO20021803L (no) Isoksazolkarboksamid-derivater
PT1237857E (pt) Novos derivados fenalquiloxi-fenilo
ATE257148T1 (de) Propargyletherderivate
DK1154988T3 (da) Mevinolinderivater
ATE374747T1 (de) Monofluoralkylderivate
DE60006703D1 (de) 4-hydroxybiphenylhydrazid-derivate
DK1187815T3 (da) 4-phenyl-pyrimidinderivater
ATE293592T1 (de) Resorcinderivate
DE60025348D1 (de) Ethansulfonyl-piperidin-derivate
NO20022867D0 (no) Syklopentenon-derivater
NO20020212D0 (no) 3-amino-2-benzyl-1-fenyl-propanderivater
TR200002831A3 (tr) Kinolin-4-Il türevleri I
DE60001736D1 (de) 1-trifluorotmethyl-4-hydroxy-7-piperidinyl-aminomethylchroman-derivate
NO20016301D0 (no) Terapeutiske midler